Were there any AGIO share sales or disposals by David Scadden in this Form 4?

No sales or disposals were reported. All four transactions are coded as acquisitions or exercises, including RSU conversions to common stock and new grants of stock options and RSUs. This reflects compensation-related equity activity rather than open-market buying or selling.

AGIOS (AGIO) director Scadden exercises RSUs and receives new stock option and RSU awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS, INC. director David Scadden increased his equity-based holdings through option and RSU activity. On June 18, 2026, he acquired 2,816 shares of common stock via the exercise of previously granted restricted stock units, bringing his direct common stock ownership to 20,419 shares.

He also received new equity awards: 14,950 stock options with a $34.16 exercise price, vesting in full on June 18, 2027, and 2,927 new restricted stock units that also vest in full on June 18, 2027. Earlier RSUs granted on June 18, 2025 will vest in full on June 18, 2026, with shares delivered within three business days after vesting.

Insider Trade Summary

2,816 shares exercised/converted

Mixed 4 txns

Insider Scadden David

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted stock units	2,816	$0.00	--
Grant/Award	Restricted stock units	2,927	$0.00	--
Grant/Award	Stock options (right to buy)	14,950	$0.00	--
Exercise	Common stock	2,816	$0.00	--

Holdings After Transaction: Restricted stock units — 0 shares (Direct, null); Stock options (right to buy) — 14,950 shares (Direct, null); Common stock — 20,419 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Key Figures

RSUs exercised into common stock: 2,816 shares Common shares held after transactions: 20,419 shares New stock option grant: 14,950 options at $34.16 +2 more

5 metrics

RSUs exercised into common stock 2,816 shares Converted to common stock on June 18, 2026

Common shares held after transactions 20,419 shares Direct ownership after June 18, 2026 activity

New stock option grant 14,950 options at $34.16 Granted June 18, 2026; vesting June 18, 2027

New RSU grant 2,927 units Granted June 18, 2026; vesting June 18, 2027

Prior RSU grant vesting 2,816 units Granted June 18, 2025; vesting June 18, 2026

Key Terms

restricted stock units, stock options (right to buy), Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more

5 terms

restricted stock units financial

"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options (right to buy) financial

"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest in full financial

"The shares underlying the stock units will vest in full on June 18, 2026."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:21 PM Accepted by SEC EDGAR 06/23/2026 - 05:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scadden David

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	06/18/2026		M		2,816	A	$0	20,419	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted stock units	⁽¹⁾	06/18/2026		M			2,816	⁽²⁾	⁽²⁾	Common stock	2,816	$0	0	D
Restricted stock units	⁽¹⁾	06/18/2026		A		2,927		⁽³⁾	⁽³⁾	Common stock	2,927	$0	2,927	D
Stock options (right to buy)	$34.16	06/18/2026		A		14,950		⁽⁴⁾	06/18/2036	Common stock	14,950	$0	14,950	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Remarks:

	/s/ William Cook, as Attorney-in-fact for David Scadden	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did AGIO director David Scadden report on June 18, 2026?

David Scadden exercised 2,816 restricted stock units into common shares and received new equity awards. These awards included 14,950 stock options and 2,927 restricted stock units, all tied to future vesting dates and normal director compensation rather than open-market trading.

How many AGIO common shares does David Scadden hold after these transactions?

After exercising 2,816 restricted stock units, David Scadden directly holds 20,419 shares of AGIOS PHARMACEUTICALS common stock. This figure reflects his position following the June 18, 2026 Form 4 activity and excludes the additional shares underlying unvested options and restricted stock units.

What are the terms of David Scadden’s new AGIO stock option grant?

Scadden received 14,950 stock options with a $34.16 exercise price. According to the disclosure, these options were granted on June 18, 2026, and the underlying shares vest 100% on June 18, 2027, aligning with typical one-year vesting for director equity compensation.

What restricted stock unit grants did David Scadden receive from AGIOS PHARMACEUTICALS?

Scadden holds two notable RSU awards. A prior grant’s 2,816 units vest in full on June 18, 2026, while a new grant of 2,927 units on June 18, 2026 vests in full on June 18, 2027. Vested shares are delivered within three business days after vesting.